Core Insights - The National Natural Science Foundation of China has officially released the 2026 project guidelines, establishing an independent discipline for "Organoids and Artificial Organs" under the life sciences sector C10, with application code C1004 [1][2]. Group 1: New Discipline Establishment - The addition of the independent discipline code marks a strategic focus on organoid and organ-on-chip research, highlighting its importance in national basic research [2][11]. - This initiative follows the earlier establishment of the "Organ-on-Chip and Systems" independent discipline under H28 "Biomedical Engineering / Regenerative Medicine" in 2025, with application code H2812 [2][11]. Group 2: Research and Evaluation Enhancements - The new code provides a dedicated platform for academic exchange and resource support, allowing researchers to focus on core areas of organoid and organ-on-chip development without the constraints of other disciplines [4][16]. - The evaluation system will become more specialized, enabling peer review to concentrate on the unique scientific logic of organoid research, thus allowing innovative studies to stand out [4][16]. Group 3: Strategic Importance - This adjustment signifies the national recognition of the core value of organoid and organ-on-chip technologies, enhancing their strategic position in the national research framework [6][19]. - The establishment of this independent category is expected to attract more research talent to the field, fostering interdisciplinary innovation and accelerating the application of technological results [10][19].

Core Viewpoint - The establishment of an independent discipline for "Organoids and Artificial Organs" under the National Natural Science Foundation's 2026 project guidelines signifies a strategic focus on this cutting-edge field, presenting unprecedented development opportunities [2][9]. Group 1: New Discipline Establishment - The new application code C1004 for "Organoids and Artificial Organs" has been introduced, marking a significant addition to the C10 discipline system of "Biomaterials, Imaging, and Tissue Engineering" [2][6]. - This initiative follows the earlier introduction of the independent discipline "Organ-on-a-Chip and Systems" under the H28 biomedical engineering category in 2025, indicating a growing emphasis on organoid and organ-on-a-chip research [2][6]. Group 2: Research Focus and Evaluation - The establishment of a dedicated code allows researchers to focus on core issues in the organoid field without the constraints of aligning with other disciplines, enhancing the depth of exploration in areas such as disease simulation models and drug screening [8][9]. - The new evaluation system is designed to better assess the unique scientific logic of organoid research, enabling innovative studies to stand out and receive appropriate recognition [7]. Group 3: Strategic Importance - This adjustment reflects the national recognition of the core value of organoid and organ-on-a-chip technologies, positioning them as key elements in overcoming bottlenecks in biomedical research and enhancing international competitiveness [9]. - The initiative aims to attract more research talent to the field, fostering interdisciplinary innovation and accelerating the application of technological advancements [9].

Core Viewpoint - The Xi'an Municipal Government has released an implementation plan to enhance the biopharmaceutical industry from 2025 to 2027, focusing on breakthroughs in key drug development technologies and supporting the research and commercialization of innovative drugs [1][2]. Group 1: Industry Goals - The plan sets three main objectives: achieving a biopharmaceutical industry scale of 40 billion yuan by 2027, with specific targets for traditional Chinese medicine (9 billion yuan), chemical drugs (12 billion yuan), biological drugs (6 billion yuan), and medical devices (13 billion yuan) [2]. - It aims to achieve clinical approval for one innovative drug and production approval for another by 2027, along with 40 Class III medical devices and 400 Class II medical devices [2]. Group 2: Innovation and Collaboration - The plan emphasizes the development of innovative drugs, particularly in areas such as targeted liver delivery drugs, peptide products, and addiction treatment drugs, while encouraging collaboration between pharmaceutical companies and academic institutions [3][4]. - It outlines a comprehensive innovation ecosystem for cell therapy, focusing on stem cell therapy, immune cell therapy, and cell-derived therapies, with a full chain from basic research to clinical application [4][5]. Group 3: Policy Support and Trends - Multiple cities, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to support the innovative drug industry, indicating a new cycle of policy support for the biopharmaceutical sector [7][8]. - The policies include expedited clinical trial approvals and financial support for innovative drug development, reflecting a trend towards enhancing the overall innovation ecosystem in the pharmaceutical industry [7][8].

Core Viewpoint - The Xi'an Municipal Government has released an implementation plan to enhance the biopharmaceutical industry from 2025 to 2027, focusing on breakthroughs in key drug development technologies and supporting the research and commercialization of innovative drugs [1][2]. Group 1: Industry Goals - The plan sets three main objectives: achieving a biopharmaceutical industry scale of 40 billion yuan by 2027, with specific targets for traditional Chinese medicine (9 billion yuan), chemical drugs (12 billion yuan), biological drugs (6 billion yuan), and medical devices (13 billion yuan) [2]. - It aims to achieve clinical approval for one innovative drug and production approval for another by 2027, as well as 40 Class III medical devices and 400 Class II medical devices [2]. Group 2: Innovation and Collaboration - The plan emphasizes the development of innovative drugs, particularly in areas such as targeted liver delivery drugs and peptide products, and encourages collaboration between pharmaceutical companies and academic institutions for research and development [3][4]. - It outlines a comprehensive innovation ecosystem for cell therapy, focusing on stem cell therapy, immune cell therapy, and cell-derived therapies, with a full chain from basic research to clinical application [4][5]. Group 3: Policy Support and Trends - Multiple cities, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to support the innovative drug industry, indicating a new cycle of policy support for the biopharmaceutical sector [7][8]. - The industry is experiencing a policy cycle that supports the entire innovative drug supply chain, with measures such as expedited clinical trial approvals and financial incentives for drug development [8].

Core Viewpoint - The Xi'an Municipal Government has released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)", aiming to advance drug research and development in key areas such as stem cell drugs and peptide drugs, while also enhancing the competitiveness of enterprises in the innovative drug sector [1][2]. Industry Development Goals - By 2027, the biopharmaceutical industry in Xi'an is expected to reach a scale of 40 billion yuan, with specific targets for traditional Chinese medicine, chemical drugs, biological drugs, medical devices, and consumer healthcare [1]. - The plan aims for the approval of 1 clinical drug and 1 production drug in the innovative drug sector, as well as 40 Class III medical devices and 400 Class II medical devices by 2027 [2]. Innovation and Collaboration - The plan emphasizes breakthroughs in core technologies for drug development, particularly in stem cell and peptide drugs, and encourages collaboration between pharmaceutical companies and academic institutions for research and development [2][3]. - A full-chain collaborative system covering research, clinical trials, approval, manufacturing, and market access is to be established to facilitate innovation in the pharmaceutical industry [2]. Focus on Cell Therapy - The plan includes a specific initiative for the industrialization of cell therapy technologies, focusing on stem cell therapy, immune cell therapy, and cell-derived therapies [3][4]. - It supports partnerships with universities and medical institutions to advance clinical research in areas such as gastric and liver cancer [3]. Policy Support Across Regions - Multiple cities, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to support the innovative drug industry, indicating a new cycle of policy support for the pharmaceutical sector [4][5]. - Specific measures include reducing clinical trial approval times and providing financial support for innovative drug development [5]. Market Outlook - Analysts note that the pharmaceutical industry is experiencing a new cycle of policy support, with a focus on "hard innovation" assets and those with strong international potential [6]. - The Chinese innovative drug sector is positioned to maintain competitive advantages in emerging technologies and disease targets, with a focus on "innovation + internationalization" as a core strategy moving forward [6].